Using cBioPortal (Cerami et al., 2012), we analysed KDM5B gene alterations in the TCGA PRAD prostate adenocarcinoma study (n = 499), the SU2C/PCF Dream Team Metastatic Prostate Adenocarcinoma study (n = 444) and the Trento/Cornell/Broad Neuroendocrine PCa study (n = 114). Here, KDM5B is linked to prostate adenocarcinoma.